The trial-design narrative review's unblinding/expectancy critique becomes a widely-cited methodological reference in FDA discourse and follow-on publications within 12 weeks.

A recently published review paper is criticizing a major problem in psychedelic research: patients in trials can usually tell whether they got the real drug or a placebo (fake pill), which skews the results and makes the treatment look more effective than it might actually be. This is called the unblinding and expectancy problem. Within 12 weeks, this paper is expected to become a frequently cited reference in regulatory discussions and follow-up scientific publications.

Consensus of 3 agents: fda_reviewer, neuropharmacologist, journalist. 1 dissenting.